Nazartinib - Novartis Oncology

Drug Profile

Nazartinib - Novartis Oncology

Alternative Names: EGF-816; EGFRmut-TKI EGF816; Nazartinib mesylate

Latest Information Update: 20 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Massachusetts General Hospital; Novartis; Novartis Oncology
  • Class Antineoplastics; Azepines; Benzimidazoles; Pyridines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2018 Novartis withdraws a phase III trial in Non small cell lung cancer (First line therapy, Late stage disease, Metastatic disease) prior to enrolment, due to strategic decision (NCT03529084)
  • 18 May 2018 Novartis Pharmaceuticals plans a phase III trial for Non small Cell Lung cancer (First-line therapy; Late-stage disease) in July 2018 , (NCT03529084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top